Westlake Village, CA, United States of America

Hsieng Sen Lu

USPTO Granted Patents = 22 (Patent Applications = 8)

CIPO Patents = 5 (Patent Applications = 2)

EPO Patents = 16 (Patent Applications = 20)

Average Co-Inventor Count = 4.0

ph-index = 7

Forward Citations = 239(Granted Patents)

Location History:

Thousand Oaks, CA (US) (1997 - 2010)
Westlake Village, CA (US) (2009 - 2020)

Company Filing History:

where one patent can have more than one assignee

Years Active: 1997-2025

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12297260 - DKK1 antibodies and methods of use (2025-05-13),

2. 12134652 - Human CGRP receptor binding proteins (2024-11-05),

3. 12122841 - Human CGRP receptor binding proteins (2024-10-22),

4. 10800839 - DKK1 antibodies and methods of use (2020-10-13),

5. 9879072 - DKK1 antibodies and methods of use (2018-01-30),

6. 9862771 - Human CGRP receptor binding proteins (2018-01-09),

7. 9353174 - Epitopes (2016-05-31),

8. 9102731 - Human CGRP receptor binding proteins (2015-08-11),

9. 8999343 - Antibodies that bind myostatin, compositions and methods (2015-04-07),

10. 8715663 - Epitopes (2014-05-06),

11. 8101184 - Treatment methods using Dkk-1 antibodies (2012-01-24),

12. 8003108 - Sclerostin epitopes (2011-08-23),

13. 7872106 - Sclerostin-binding antibodies (2011-01-18),

14. 7794970 - Method for generating F(ab')2 antibody fragments (2010-09-14),

15. 7709611 - Antibodies to Dkk-1 (2010-05-04),

Hsieng Sen Lu: Innovator in CGRP Receptor Binding Proteins

Introduction

Hsieng Sen Lu is a prominent inventor based in Westlake Village, California. With an impressive portfolio of 21 patents, he has made significant contributions to the field of biotechnology, particularly in the area of CGRP receptor binding proteins. His work focuses on developing innovative solutions to combat various health disorders, including migraine headaches.

Latest Patents

Among his recent inventions are patents related to human CGRP receptor binding proteins. These antigen binding proteins are designed to bind to the human CGRP receptor (CGRP R). The innovations include nucleic acids encoding the antigen binding proteins, vectors, and cells that produce these proteins. Notably, these binding proteins inhibit the interaction between CGRP R and CGRP, which is critical in addressing CGRP R-related disorders. This technology holds promise for the treatment and/or prevention of migraine headaches, showcasing the scientific advancements made by Lu in his research.

Career Highlights

Hsieng Sen Lu has a distinguished career with notable affiliations in the biotechnology sector. He has worked with prominent companies, including Amgen Inc. and UCB S.A., where he has contributed to groundbreaking research and development efforts. His academic and professional pursuits have enabled him to push the boundaries of innovation in his field.

Collaborations

Throughout his career, Hsieng Sen Lu has collaborated with esteemed colleagues, including Christopher J. Paszty and Wenyan Shen. These collaborations have fostered a productive environment for innovation, leading to the development of valuable technologies within the medical and scientific communities.

Conclusion

Hsieng Sen Lu’s achievements in the realm of CGRP receptor binding proteins underscore his commitment to advancing medical science. With 21 patents to his name, his work continues to pave the way for therapeutic advancements, particularly in the treatment of migraines. His collaborations and career milestones reflect a dedication to innovation that places him at the forefront of his field.

This text is generated by artificial intelligence and may not be accurate.